MSN to launch generic anti-COVID pill Molnupiravir
New Delhi: Pharmaceuticals firm MSN Group on Thursday said it will launch its generic anti-COVID-19 pill Molnupiravir under the brand 'Molulow' in India.
The group is all set to launch the generic Molnupiravir 200 mg capsules and it is being manufactured at its USFDA and MHRA accredited facility based out of Hyderabad, MSN Group said in a statement. Molulow will come as a pack of 4x10 capsule strips with each capsule in 200 mg strength.
Last month, the Drugs Controller General of India (DCGI) approved Molnupiravir for restricted use in emergency situation (EUA) in India. Other homegrown pharma majors such as Strides Pharma, Dr Reddy's, Sun Pharma, Cipla, Hetero, Torrent, Optimus and Brinton Pharma have already announced plans to roll out their generic versions of the drug.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.